Healthcare perspectives from The Economist Intelligence Unit

Color

#DB444B

Hero Carousel

Spotlight

Bringing healthcare to hard-hit areas in Bangladesh

YouTube

https://www.youtube.com/channel/UCQDMOSbJtqrtNzif5rS22OQ

Slideshare

http://www.slideshare.net/economistintelligenceunit

Pinterest

https://www.pinterest.com/theeiu/

Healthcare spending: To have and have not

The provision of healthcare to women—like the supply of so much else in life—is and will remain a tale of haves and have-nots. In wealthy countries, healthcare spending is huge and is expected to keep climbing for the rest of this decade. In middle-income countries, healthcare spending is rising as well, but from a much lower base. In absolute terms, the gap in healthcare provision between rich and middle income countries will remain large for the rest of this decade.

 

The changing biopharma risk equation

Pharmaceutical companies are in an expansive mode. With rapid advances being made in the development of new therapies, including stem-cell derived therapies and gene therapies, and a growing cohort of potential customers in the burgeoning middle classes of emerging markets, expansion into both new product categories and geographic regions is a priority for most companies.

The changing biopharma risk equation

Pharmaceutical companies are in an expansive mode. With rapid advances being made in the development of new therapies, including stem-cell derived therapies and gene therapies, and a growing cohort of potential customers in the burgeoning middle classes of emerging markets, expansion into both new product categories and geographic regions is a priority for most companies.

The changing biopharma risk equation

However, this class of product—ranging from well-established large-molecule drugs to truly novel therapies—poses major challenges because of their scientific complexity and sophisticated development requirements. Furthermore, expanding the drug pipeline isn’t the only growth strategy most companies are pursuing: They are also planning to expand geographically and expect to face various risks doing so, including unfamiliar regulatory environments, shifts in pricing and customers’ ability to pay.

Confronting obesity in Sweden

The rise in the number of overweight people in Sweden has driven efforts to promote stronger public-health campaigns, increase the amount of research into obesity and boost the impact of different approaches to combatting and treating it. At the same time, there remains at least a partial disconnect between research and initiatives at the municipal and regional levels on the one hand, and efforts to create a more integrated national approach to obesity on the other.

 

Confronting obesity in Denmark

Education and prevention programmes are largely operated at the national level, while treatment of both children and adults is the responsibility of the counties and municipal governments. Childhood obesity has been a particular focus.

Initial prevention programmes in Denmark over the past decade have focused on broad guidelines for improving diet and levels of physical activity; however, they have failed to include specific targets or timelines. 

 

Confronting obesity in Spain

Moreover, the decentralisation of Spanish healthcare makes obesity policy primarily the responsibility of the country’s 17 autonomous regions, making it more difficult to bring about a truly integrated approach to the condition, those interviewed for this case study say.

 

How mobility impacts the performance of healthcare providers

Sponsored By

Consumer health: time for a regulatory re-think?

This greater use of OTC pharmaceuticals is consistent with the policy of many governments to increase the role of patients in their own health, improve access to medications where consistent with safety, and to reduce costs to health systems. 

Consumer health: time for a regulatory re-think?

This greater use of OTC pharmaceuticals is consistent with the policy of many governments to increase the role of patients in their own health, improve access to medications where consistent with safety, and to reduce costs to health systems. 

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week